MedPath

Study of Phosphate Levels in Patients With Chronic Kidney Disease

Phase 2
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: 5.0 g PA21 (1,000 mg iron)
Drug: 7.5 g PA21 (1,500 mg iron)
Drug: 10.0 g PA21 (2,000 mg iron)
Drug: 12.5 g PA21 (2,500 mg iron)
Drug: 1.25 g PA21 (250 mg iron)
Registration Number
NCT00824460
Lead Sponsor
Vifor Pharma
Brief Summary

The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
154
Inclusion Criteria
  • ≥ 18 years of age,
  • Receiving stable maintenance hemodialysis 3 times a week
  • On restricted phosphate diet at screening and throughout study
  • Receiving stable dose of phosphate binder for at least 1 month
  • Serum phosphate levels >1.78 mmol/L

Main

Exclusion Criteria
  • Uncontrolled hyperphosphatemia
  • Hypercalcemia at screening or during washout
  • Serum calcium < 1.9 mmol/L (<7.6 mg/dL)
  • Severe hyperparathyroidism (iPTH levels >600 ng/L)
  • Pregnancy or lactation
  • Iron deficiency anemia
  • History of hemochromatosis or ferritin >800 mg/L,
  • Hepatitis B, hepatitis C or other significant concurrent liver disorders
  • Known positivity to HIV
  • Use of oral iron preparations 1 month before screening,
  • Serious medical condition or uncontrolled systemic disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
5.0 g PA215.0 g PA21 (1,000 mg iron)-
7.5 g PA217.5 g PA21 (1,500 mg iron)-
10.0 g PA2110.0 g PA21 (2,000 mg iron)-
12.5 g PA2112.5 g PA21 (2,500 mg iron)-
1.25 g PA211.25 g PA21 (250 mg iron)-
Sevelamer hydrochloride - active controlSevelamer hydrochloride-
Primary Outcome Measures
NameTimeMethod
Change From Baseline in Serum-phosphate Levels at the End of Treatment.6 weeks after baseline
Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Serum-phosphate Levels at Week 22 weeks after baseline
Change From Baseline in Serum-phosphate Levels at Week 44 weeks after baseline
Change From Baseline in Serum-phosphate Levels at Week 55 weeks after baseline

Trial Locations

Locations (56)

UMHAT "Sveti Ivan Rilski"

🇧🇬

Sofia, Bulgaria

MDHAT Department of Haemodialysis and Nephrology

🇧🇬

Veliko Tarnovo, Bulgaria

Innef a.s. Hemodialyzancni stredisko

🇨🇿

Brno, Czech Republic

UMHAT "Alexandrovska" Dialysis Clinic

🇧🇬

Sofia, Bulgaria

Nemocnice s poliklinikou v Novem Jicine

🇨🇿

Novy Jicin, Czech Republic

Katedra i Klinika Nefrologii

🇵🇱

Poznań, Poland

NZOZ Dializa

🇵🇱

Olkusz, Poland

Spitalul Clinic

🇷🇴

Lasi, Romania

S.C. Avitum S.R.L

🇷🇴

Targu Mures, Romania

Saint-Petersburg CUS City Mariinskaya Hospital

🇷🇺

St. Petersburg, Russian Federation

CUS City Hospital

🇷🇺

St.Petersburg, Russian Federation

Kantonspital Aarau

🇨🇭

Aarau, Switzerland

Saint-Petersburg GUZ City Clinical Hospital

🇷🇺

St. Petersburg, Russian Federation

Universitatsspital Zurich

🇨🇭

Zürich, Switzerland

Nephrologische Gemeinschaftspraxis und Dialysezentrum

🇩🇪

Dortmund, Germany

Samodzielny Specjalistyczny

🇵🇱

Siedlce, Poland

MHAT

🇧🇬

Gabrovo, Bulgaria

SHATCVD - National Cardiology Hospital

🇧🇬

Sofia, Bulgaria

Western Nephrology & Metabolic Disease

🇺🇸

Arvada, Colorado, United States

Opca bonica Bjelovar

🇭🇷

Bjelovar, Croatia

MHAT Plovdiv

🇧🇬

Plovdiv, Bulgaria

Klinicka bolnica Dubrava

🇭🇷

Zagreb, Croatia

GOU VPO

🇷🇺

St. Petersburg, Russian Federation

Chuv Lausanne

🇨🇭

Lausanne, Switzerland

Southwest Houston Research

🇺🇸

Houston, Texas, United States

Pines Clinical Research

🇺🇸

Pembroke Pines, Florida, United States

University Hospitals / Case Medical Center

🇺🇸

Cleveland, Ohio, United States

Southeast Renal Research Institute

🇺🇸

Chattanooga, Tennessee, United States

Complete Renal Care

🇺🇸

Denver, Colorado, United States

Nephrology Associates

🇺🇸

Nashville, Tennessee, United States

Department of Haemodialysis at MHAT

🇧🇬

Ruse, Bulgaria

5th MHAT Sofia

🇧🇬

Sofia, Bulgaria

UMHAT "Sveta Anna"

🇧🇬

Sofia, Bulgaria

MHAT "Tokuda Hospital Sofia"

🇧🇬

Sofia, Bulgaria

Opca bolnica Karlovac

🇭🇷

Karlovac, Croatia

Opca bolnica

🇭🇷

Koprivnica, Croatia

Klinicka bolnica Osijek

🇭🇷

Osijek, Croatia

Klinicki bolnicki centar Split

🇭🇷

Split, Croatia

Klinicki bolnicki centar Rijeka

🇭🇷

Rijeka, Croatia

Klinicka bolnica

🇭🇷

Zagreb, Croatia

Opca bolnica Zadar

🇭🇷

Zadar, Croatia

Poliklinika Sveti Duh II

🇭🇷

Zagreb, Croatia

Nemocnice Nove Mesto na Morave

🇨🇿

Nove Město na Morave, Czech Republic

Klinika nefrologie VFN

🇨🇿

Prague, Czech Republic

Marienhospital

🇩🇪

Herne, Germany

Niepubliczny Zaklad Opieki Zdrowotnej

🇵🇱

Sieradz, Poland

Centrum Dializy i Diagnostyki

🇵🇱

Warszawa, Poland

Institutul Clinic Fundeni

🇷🇴

Bucuresti, Romania

Spitalul Universitar de Urgenta Bucuresti

🇷🇴

Bucuresti, Romania

SC Renamed Nefrodial SRL

🇷🇴

Oradea, Romania

MLPU Clinical City Hospital

🇷🇺

Smolensk, Russian Federation

GOU VPO Kazan

🇷🇺

Kazan, Russian Federation

GUZ City Clinical Hospital

🇷🇺

Moscow, Russian Federation

MUZ City Clinical Hospital

🇷🇺

Novosibirsk, Russian Federation

Saint-Petersburg GUZ City Hospital

🇷🇺

St. Petersburg, Russian Federation

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath